Author/Authors :
J. A. Reynoldson، نويسنده , , J. M. BEHNKE، نويسنده , , Helen M. Gracey، نويسنده , , R. J. Horton، نويسنده , , R. Spargo، نويسنده , , R. M. Hopkins، نويسنده , , C. C. Constantine، نويسنده , , F. Gilbert، نويسنده , , C. Stead، نويسنده , , R. P. Hobbs، نويسنده , , R. C. A. THOMPSON، نويسنده ,
Abstract :
The parasitological, clinical efficacy and tolerability of albendazole in the treatment for both giardiasis and hookworm infection in a remote Aboriginal population was investigated. Albendazole at a dose rate of 400 mg daily for 5 days was highly effective in reducing hookworm egg numbers and both Giardia antigen and cysts. The 36.6% prevalence of Giardia prior to treatment fell to 12% between days 6 and 9, 15% for days 10–17 and rose to 28% between days 18 and 30. Tolerability and clinical efficacy were excellent. The effect of albendazole on hookworm was longer lasting than that on Giardia, reducing percent infection from over 76–2% on days 6–9 and zero by day 18–30 despite conditions highly conducive to rapid re-infection. We conclude that albendazole is highly efficacious against both parasites when used as described but that long term community benefit may require additional education programmes to avoid re-infection with Giardia although treatment strategies would seem appropriate for hookworm.
Keywords :
Hookworm , Acylostoma duodenale , Giardia duodenalis , Albendazole